Epimacular brachytherapy for wet AMD: current perspectives

Ricardo P Casaroli-Marano,1,2 Socorro Alforja,1 Joan Giralt,1 Michel E Farah2 1Instituto Clínic de Oftalmología (Hospital Clínic de Barcelona), University of Barcelona, Barcelona, Spain; 2Department of Ophthalmology and Visual Sciences, Universidade Federal de Sao...

Full description

Bibliographic Details
Main Authors: Casaroli-Marano RP, Alforja S, Giralt J, Farah ME
Format: Article
Language:English
Published: Dove Medical Press 2014-08-01
Series:Clinical Ophthalmology
Online Access:http://www.dovepress.com/epimacular-brachytherapy-for-wet-amd-current-perspectives-peer-reviewed-article-OPTH
id doaj-b5203c35538445f3b3e7f156c7aeb450
record_format Article
spelling doaj-b5203c35538445f3b3e7f156c7aeb4502020-11-24T22:39:53ZengDove Medical PressClinical Ophthalmology1177-54832014-08-012014default1661167018127Epimacular brachytherapy for wet AMD: current perspectivesCasaroli-Marano RPAlforja SGiralt JFarah ME Ricardo P Casaroli-Marano,1,2 Socorro Alforja,1 Joan Giralt,1 Michel E Farah2 1Instituto Clínic de Oftalmología (Hospital Clínic de Barcelona), University of Barcelona, Barcelona, Spain; 2Department of Ophthalmology and Visual Sciences, Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Sao Paulo, Brazil Abstract: Age-related macular degeneration (AMD) is considered the most common cause of blindness in the over-60 age group in developed countries. There are basically two forms of presentation: geographic (dry or atrophic) and wet (neovascular or exudative). Geographic atrophy accounts for approximately 85%–90% of ophthalmic frames and leads to a progressive degeneration of the retinal pigment epithelium and the photoreceptors. Wet AMD causes the highest percentage of central vision loss secondary to disease. This neovascular form involves an angiogenic process in which newly formed choroidal vessels invade the macular area. Today, intravitreal anti-angiogenic drugs attempt to block the angiogenic events and represent a major advance in the treatment of wet AMD. Currently, combination therapy for wet AMD includes different forms of radiation delivery. Epimacular brachytherapy (EMBT) seems to be a useful approach to be associated with current anti-vascular endothelial growth factor agents, presenting an acceptable efficacy and safety profile. However, at the present stage of research, the results of the clinical trials carried out to date are insufficient to justify extending routine use of EMBT for the treatment of wet AMD. Keywords: macular degeneration, radiation, vascular endothelial growth factor, combined therapy, intravitreal therapy, vitrectomyhttp://www.dovepress.com/epimacular-brachytherapy-for-wet-amd-current-perspectives-peer-reviewed-article-OPTH
collection DOAJ
language English
format Article
sources DOAJ
author Casaroli-Marano RP
Alforja S
Giralt J
Farah ME
spellingShingle Casaroli-Marano RP
Alforja S
Giralt J
Farah ME
Epimacular brachytherapy for wet AMD: current perspectives
Clinical Ophthalmology
author_facet Casaroli-Marano RP
Alforja S
Giralt J
Farah ME
author_sort Casaroli-Marano RP
title Epimacular brachytherapy for wet AMD: current perspectives
title_short Epimacular brachytherapy for wet AMD: current perspectives
title_full Epimacular brachytherapy for wet AMD: current perspectives
title_fullStr Epimacular brachytherapy for wet AMD: current perspectives
title_full_unstemmed Epimacular brachytherapy for wet AMD: current perspectives
title_sort epimacular brachytherapy for wet amd: current perspectives
publisher Dove Medical Press
series Clinical Ophthalmology
issn 1177-5483
publishDate 2014-08-01
description Ricardo P Casaroli-Marano,1,2 Socorro Alforja,1 Joan Giralt,1 Michel E Farah2 1Instituto Clínic de Oftalmología (Hospital Clínic de Barcelona), University of Barcelona, Barcelona, Spain; 2Department of Ophthalmology and Visual Sciences, Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Sao Paulo, Brazil Abstract: Age-related macular degeneration (AMD) is considered the most common cause of blindness in the over-60 age group in developed countries. There are basically two forms of presentation: geographic (dry or atrophic) and wet (neovascular or exudative). Geographic atrophy accounts for approximately 85%–90% of ophthalmic frames and leads to a progressive degeneration of the retinal pigment epithelium and the photoreceptors. Wet AMD causes the highest percentage of central vision loss secondary to disease. This neovascular form involves an angiogenic process in which newly formed choroidal vessels invade the macular area. Today, intravitreal anti-angiogenic drugs attempt to block the angiogenic events and represent a major advance in the treatment of wet AMD. Currently, combination therapy for wet AMD includes different forms of radiation delivery. Epimacular brachytherapy (EMBT) seems to be a useful approach to be associated with current anti-vascular endothelial growth factor agents, presenting an acceptable efficacy and safety profile. However, at the present stage of research, the results of the clinical trials carried out to date are insufficient to justify extending routine use of EMBT for the treatment of wet AMD. Keywords: macular degeneration, radiation, vascular endothelial growth factor, combined therapy, intravitreal therapy, vitrectomy
url http://www.dovepress.com/epimacular-brachytherapy-for-wet-amd-current-perspectives-peer-reviewed-article-OPTH
work_keys_str_mv AT casarolimaranorp epimacularbrachytherapyforwetamdcurrentperspectives
AT alforjas epimacularbrachytherapyforwetamdcurrentperspectives
AT giraltj epimacularbrachytherapyforwetamdcurrentperspectives
AT farahme epimacularbrachytherapyforwetamdcurrentperspectives
_version_ 1725707092067614720